glp-1 agonist structure Glucagon-like peptide-1 receptor GLP-1 receptor agonist-1 | CAS#:2230197-64-3

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

To overcome this limitation, various modifications and delivery strategies to enhance the pharmacokinetic properties and therapeutic efficacy of GLP-1 analogs have been studied

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

Are you a candidate?

Berberine is a plant alkaloid affecting glucose metabolism at the cellular level, while GLP-1 agonists regulate appetite and insulin secretion through hormone signaling